We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly and TRexBio Ink Deal to Develop Drugs for Immune-Mediated Diseases
Eli Lilly and TRexBio Ink Deal to Develop Drugs for Immune-Mediated Diseases
Eli Lilly and South San Francisco, Calif.-headquartered TRexBio have inked a multi-year research collaboration and licensing deal potentially worth up to $1.1 billion to develop therapies for immune-mediated diseases.